Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Medtronic beats estimates; BTIG Upgrade to Buy targets upside at $90

Jun 4, 2026, 3:11 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong earnings beat, sustained organic growth, and a fresh Buy rating with a concrete price target create a favorable re-rating dynamic; risk includes mixed targets (104 vs 90) and broader large-cap MedTech valuation shifts.

AI summary

What happened, with direct paths to the underlying reporting

Medtronic posted an earnings beat with adjusted EPS of $1.55 and revenue of $9.81B, up 9.9%. Cardiovascular sales rose 13.8% YoY to $3.80B, bolstering growth momentum. BTIG upgraded MDT to Buy with a $90 target, while Leerink trimmed its forecast to $104, signaling near-term upside amid improving organic growth.

Adjusted EPS $1.55 vs $1.54 est; Revenue $9.81B, +9.9% YoY.
Cardiovascular revenue $3.80B, +13.8% YoY (organic +10.1%).
BTIG upgrades MDT to Buy with a $90 target.
Leerink lowers price target to $104; MDT remains top 2026 pick by Kratky.
MDT shares rose about 4.3% to $81.30 on the news.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Medtronic beats estimates; BTIG Upgrade to Buy targets upside at $90

Medtronic beats Q4 and FY2026 on growth via acquisitions

Medtronic Q4 Beat Driven by Steady Cardiac Device Demand

Medtronic to Acquire SPR Therapeutics for $650 Million

MDT Gains FDA Approval for Expanded Surgical System Applications